These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17620855)

  • 1. Antisense apolipoprotein B therapy: where do we stand?
    Akdim F; Stroes ES; Kastelein JJ
    Curr Opin Lipidol; 2007 Aug; 18(4):397-400. PubMed ID: 17620855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?
    Ito MK
    Ann Pharmacother; 2007 Oct; 41(10):1669-78. PubMed ID: 17848425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein B synthesis inhibition: results from clinical trials.
    Visser ME; Kastelein JJ; Stroes ES
    Curr Opin Lipidol; 2010 Aug; 21(4):319-23. PubMed ID: 20508521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.
    Toth PP
    J Clin Lipidol; 2013; 7(3 Suppl):S6-10. PubMed ID: 23642326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense therapy in the treatment of hypercholesterolemia.
    Lippi G; Favaloro EJ
    Eur J Intern Med; 2011 Dec; 22(6):541-6. PubMed ID: 22075277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
    Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
    Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
    Bell DA; Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis.
    Crooke RM; Graham MJ; Lemonidis KM; Whipple CP; Koo S; Perera RJ
    J Lipid Res; 2005 May; 46(5):872-84. PubMed ID: 15716585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
    Yu RZ; Lemonidis KM; Graham MJ; Matson JE; Crooke RM; Tribble DL; Wedel MK; Levin AA; Geary RS
    Biochem Pharmacol; 2009 Mar; 77(5):910-9. PubMed ID: 19056355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mipomersen sodium: a new option for the treatment of familial hypercholesterolemia.
    Haddley K
    Drugs Today (Barc); 2011 Dec; 47(12):891-901. PubMed ID: 22348914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia.
    Burnett JR
    Curr Opin Mol Ther; 2006 Oct; 8(5):461-7. PubMed ID: 17078389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis.
    Ishigaki Y; Katagiri H; Gao J; Yamada T; Imai J; Uno K; Hasegawa Y; Kaneko K; Ogihara T; Ishihara H; Sato Y; Takikawa K; Nishimichi N; Matsuda H; Sawamura T; Oka Y
    Circulation; 2008 Jul; 118(1):75-83. PubMed ID: 18559699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic delivery: the last hurdle?
    Nielsen PE
    Gene Ther; 2005 Jun; 12(12):956-7. PubMed ID: 15759014
    [No Abstract]   [Full Text] [Related]  

  • 14. Mipomersen.
    Am J Cardiovasc Drugs; 2010; 10(4):271-9. PubMed ID: 20653334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.
    Yu RZ; Kim TW; Hong A; Watanabe TA; Gaus HJ; Geary RS
    Drug Metab Dispos; 2007 Mar; 35(3):460-8. PubMed ID: 17172312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA interference to target lipid disorders.
    Rondinone CM
    Curr Opin Lipidol; 2008 Jun; 19(3):285-8. PubMed ID: 18460920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice.
    Yu XX; Murray SF; Watts L; Booten SL; Tokorcheck J; Monia BP; Bhanot S
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E436-45. PubMed ID: 18523126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human cholesterol metabolism and therapeutic molecules.
    Charlton-Menys V; Durrington PN
    Exp Physiol; 2008 Jan; 93(1):27-42. PubMed ID: 18165431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.